> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# BioNTech's HER2-Low Breast Cancer Drug Hits Its Trial Goal, But The Companies Call The Likely Benefit 'Limited'
- URL: https://www.bullished.co/biontechs-her2-low-breast-cancer-drug-hits-its-trial-goal-but-the-companies-call-the-4ca8e36f/
- Published: 2026-10-26T10:27:04.000Z
- Updated: 2026-10-26T10:27:04.000Z
- Description: A 541-patient late-stage trial showed a modest progression-free survival gain, with more lung disease than in earlier studies of the drug.
- Author: Matteo Parrino
- Tags: SEC Filings, BNTX, Industry: Healthcare

[BioNTech](https://www.bullished.co/tag/bntx/) and its partner DualityBio said their late-stage breast cancer trial [met its main goal](https://www.sec.gov/Archives/edgar/data/1776985/000177698526000074/a991261025%5Fbntxdbxtpamxtop.htm?ref=bullished.co), but the gain was modest and the companies themselves expect the benefit to patients to be limited. The release, dated Monday, also reported a higher rate of interstitial lung disease than in earlier trials of the drug, trastuzumab pamirtecan.

## A win on paper, a modest one in practice

The DYNASTY-Breast02 trial showed a statistically significant but modest improvement in progression-free survival, the time before the cancer worsens. The comparison was against chemotherapy chosen by the investigator, in patients with HR+/HER2-low metastatic breast cancer whose disease had progressed on endocrine therapy and who had not yet had chemotherapy.

The trial [randomized 541 patients](https://www.sec.gov/Archives/edgar/data/1776985/000177698526000074/a991261025%5Fbntxdbxtpamxtop.htm?ref=bullished.co) with HER2-low expression 1:1 to trastuzumab pamirtecan or a single chemotherapy drug: capecitabine, paclitaxel or nab-paclitaxel. Overall survival, a secondary measure, was not mature at this interim analysis.

The companies were blunt about what it adds up to. The data so far "suggest that the [potential benefit](https://www.sec.gov/Archives/edgar/data/1776985/000177698526000074/a991261025%5Fbntxdbxtpamxtop.htm?ref=bullished.co) to patients would be limited" in the current treatment landscape for this cancer, they said.

## More lung disease than before

Interstitial lung disease, a lung condition, appeared at a higher rate than in prior trastuzumab pamirtecan trials. Most cases were Grade 1 and 2, while severe and fatal events (Grade 3-5) occurred in a small proportion of patients.

Otherwise, the companies said, the safety profile matched earlier trials and no new safety signals appeared.

## The drug and its developers

BioNTech, the Mainz-based immunotherapy company behind the COVID-19 vaccine Comirnaty, focuses mainly on oncology. Trastuzumab pamirtecan is a third-generation antibody-drug conjugate targeting HER2, built from DualityBio's platform and developed jointly by the two companies.

The drug is also in a Phase 3 trial in HER2-expressing recurrent endometrial cancer and a Phase 1/2 trial in advanced or metastatic solid tumors. BioNTech's market value was $22.1 billion in Monday's pre-market reporting.

The companies said they will discuss the data and determine next steps.

The two companies' next step is a discussion of the data; their release sets no date for it.

### Sources

- [Form 6-K — BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer MAINZ, Germ](https://www.sec.gov/Archives/edgar/data/1776985/000177698526000074/a991261025%5Fbntxdbxtpamxtop.htm?ref=bullished.co) — SEC EDGAR
- [BioNTech (BNTX) Expanded Its Oncology Pipeline, Is It Still 25% Below Fair Value?](https://finance.yahoo.com/healthcare/articles/biontech-bntx-expanded-oncology-pipeline-141650881.html?ref=bullished.co) — Yahoo Finance
- [BioNTech and DualityBio Announce Topline Results of the](https://www.globenewswire.com/news-release/2026/10/26/3387866/0/en/biontech-and-dualitybio-announce-topline-results-of-the-dynasty-breast02-global-phase-3-clinical-trial-evaluating-trastuzumab-pamirtecan-in-hr-her2-low-metastatic-breast-cancer.html?ref=bullished.co) — globenewswire.com
- [BioNTech und DualityBio geben Topline-Ergebnisse der](https://www.globenewswire.com/news-release/2026/10/26/3387866/0/de/biontech-und-dualitybio-geben-topline-ergebnisse-der-globalen-klinischen-phase-3-studie-dynasty-breast02-f%c3%bcr-trastuzumab-pamirtecan-bei-metastasiertem-hr-her2-low-brustkrebs-bekann.html?ref=bullished.co) — globenewswire.com
- [BioNTech and DualityBio Announce Topline Results of the](https://www.globenewswire.com/de/news-release/2026/10/26/3387866/0/en/biontech-and-dualitybio-announce-topline-results-of-the-dynasty-breast02-global-phase-3-clinical-trial-evaluating-trastuzumab-pamirtecan-in-hr-her2-low-metastatic-breast-cancer.html?ref=bullished.co) — globenewswire.com

### More on BioNTech

- [BioNTech Plans To Swap Chemotherapy For Gilead's Trodelvy In Its Pumitamig Breast Cancer Trial](https://www.bullished.co/biontech-plans-to-swap-chemotherapy-for-gileads-trodelvy-in-its-pumitamig-breast-cancer-a037d14a/)
- [BioNTech's BNT113 Misses First Of Two Main Goals In Head And Neck Cancer Trial](https://www.bullished.co/biontechs-bnt113-misses-first-of-two-main-goals-in-head-and-neck-cancer-trial-3658c42f/)

[All BioNTech (BNTX) coverage →](https://www.bullished.co/tag/bntx/)